ENTA Enanta Pharmaceuticals Inc. Total Asset Value of Company

ENTA (Enanta) - company brandmark

Enanta Pharmaceuticals management ensures transparent oversight of development and strict capital expenditure. The stock price history demonstrates the dynamics of assets, which currently stand at 298.96. A steady inflow of licensing fees is balanced by significant investments in proprietary projects. Meanwhile, Enanta Pharmaceuticals is expanding therapy options for hepatitis and coronavirus, leveraging strategic alliances with global pharma behemoths.

ENTA (Enanta Pharmaceuticals) Company Total Assets history from 07/04/2022 to 10/31/2026

Analytical breakdowns and data insights for company Enanta (ENTA)

- market value and analyst target forecast:
Stock Price enanta.com|ENTA - Price Target Chart
- market capitalization data:
Market Valuation Enanta Pharmaceuticals, Inc|ENTA - Enterprise Value
- issuer book value statistics:
Accounting Value of a Share Enanta Pharmaceuticals|ENTA - Book Capitalization|Market Capitalization to Book Value Ratio enanta.com|ENTA - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Enanta Pharmaceuticals|ENTA - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Enanta Pharmaceuticals, Inc|ENTA - Company Aggregate Debts|Debts to Book Capitalization Enanta Pharmaceuticals, Inc|ENTA - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Enanta Pharmaceuticals|Quick Liquidity enanta.com
- net income and valuation multiples indicators:
ENTA - Net Profit
Fundamental valuation:Enanta Pharmaceuticals
Manufactured products of Enanta Pharmaceuticals

Enanta Pharmaceuticals (ENTA) is successfully transforming its portfolio by shifting development focus from hepatitis to current antiviral drugs for RSV therapy. The GURU.Markets toolkit allows for a reverse assessment of the issuer's total capital and debt load via ROA asset magnitude. The growth of this metric confirms the expansion of the resource base required to implement new innovative programs. The stable dynamics of this indicator minimize the risk of impairment and guarantee the resilience of market quotes.

Key competitors

gilead.com (GILD) - Company Total Assets|Aggregate Company Assets cidara.com|Novavax Inc - Total Asset Value of Company|Company Total Assets CVAC|VALN (Valneva Vaccines) - Aggregate Asset Value|Company Total Assets VIR (Vir Biotechnology, Inc.)|Company Total Assets siga.com SIGA|EBS - Aggregate Company Assets|Aggregate Asset Value AVIR (Atea Pharma)|invivyd.com (IVVD) - Aggregate Company Assets|Cumulative Company Assets Inovio Pharma|HLVX (HilleVax, Inc.) - Company Total Assets|Company Total Assets kalaristx.com|Cumulative Company Assets DYAI (Dyadic International)|NNVC (nanoviricides.com) - Aggregate Asset Value|Talphera Corp - Cumulative Company Assets|Cocrystal Pharma Corp - Aggregate Company Assets|Traws Therapeutics - Company Total Assets|Company Total Asset Base Dogwood Therapeutics, Inc. DWTX|Qualigen Therapeutics, Inc. (QLGN) - Aggregate Company Assets|AlloVir - Aggregate Asset Value|Cumulative Company Assets VBIV|Company Total Assets Virios|Aggregate Company Assets Vaxart, Inc. (VXRT)